Since treatment of primary human hepatocytes with palmitic or oleic acids did not alter CCN2 production, it was speculated that elevated expression of CCN2 and TGF-β during the inflammatory phase of NASH renders the liver more susceptible to developing fibrosis. Here, TGFB1 is linked to metabolic dysfunction-associated steatohepatitis.